{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:25:03Z","timestamp":1792081503783,"version":"4.4.0"},"reference-count":30,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2024,6,17]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n<jats:title>\n<jats:named-content content-type=\"\">Background<\/jats:named-content>\n<\/jats:title>\n<jats:p>\n<jats:named-content content-type=\"\">ART forgiveness is the ability of a regimen to maintain HIV-RNA suppression despite a documented imperfect adherence. We explored forgiveness of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF).<\/jats:named-content>\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>\n<jats:named-content content-type=\"\">Methods<\/jats:named-content>\n<\/jats:title>\n<jats:p>\n<jats:named-content content-type=\"\">In this retrospective cohort study pharmacy drug refills were used to calculate the proportion of days covered (PDC) as a proxy of adherence. Forgiveness was defined as the possibility to achieve a selected HIV-RNA threshold by a given level of imperfect adherence. A logistic model was applied to verify the impact of baseline variables and adherence on the virologic outcomes.<\/jats:named-content>\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>\n<jats:named-content content-type=\"\">Results<\/jats:named-content>\n<\/jats:title>\n<jats:p>\n<jats:named-content content-type=\"\">We enrolled 420 adults. From them, 787 one-year time-periods were derived for a median cohort follow-up of 873 person\/years.<\/jats:named-content>\n<\/jats:p>\n<jats:p>\n<jats:named-content content-type=\"\">Most of them were males (73.1%); the most frequent risk factor for HIV infection was heterosexual contacts (49.5% of cases), followed by 22.5% MSM and 22.5% intravenous drug users. The median age of enrolled persons with HIV was 51 years (IQR 45-57 years); the median duration of HIV infection was 7.9 years (IQR 4-18 years) and the median nadir of CD4 cells was 277 cells\/mcL (IQR 100-513 cells\/mcL).<\/jats:named-content>\n<\/jats:p>\n<jats:p>\n<jats:named-content content-type=\"\">Adherence showed a median of 0.97 (IQR 0.91-1.00), consequently only 17 time-periods (2.2%) in 17 different individuals (4.0%) showed HIV-RNA blood levels above 200 copies\/ml.<\/jats:named-content>\n<\/jats:p>\n<jats:p>\n<jats:named-content content-type=\"\">A PDC of 0.75 was sufficient to obtain in &gt; 90% of cases the virologic outcome for both 200 copies\/ml or 50 copies\/ml. An adherence value of 0.85 obtained a positive response in virtually all subjects either for a cut-off of 50 or 200 copies\/ml.<\/jats:named-content>\n<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>\n<jats:named-content content-type=\"\">Conclusions<\/jats:named-content>\n<\/jats:title>\n<jats:p>\n<jats:named-content content-type=\"\">Long-term success of ART needs effective, well tolerated, friendly regimens. Adherence remains a crucial determinant of long-term success, but suboptimal adherence levels are relatively common. Given this, an elevated forgiveness plays a relevant role to further improve long-term outcomes and should be considered a fundamental characteristic of any antiretroviral regimen. B\/F\/TAF has been proved to have all of these characteristics.<\/jats:named-content>\n<\/jats:p>\n<\/jats:sec>","DOI":"10.1136\/sextrans-2024-056202","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T17:20:49Z","timestamp":1720113649000},"page":"418-422","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["B\/F\/TAF forgiveness to non-adherence"],"prefix":"10.1136","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9791-0072","authenticated-orcid":false,"given":"Franco","family":"Maggiolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6622-6358","authenticated-orcid":false,"given":"Lucia","family":"Taramasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Blanchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Centorrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Biagio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"2024101702550763000_100.7.418.1","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2024101702550763000_100.7.418.2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003865"},{"key":"2024101702550763000_100.7.418.3","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002137"},{"key":"2024101702550763000_100.7.418.4","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13319"},{"key":"2024101702550763000_100.7.418.5","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"2024101702550763000_100.7.418.6","doi-asserted-by":"publisher","DOI":"10.1086\/426595"},{"key":"2024101702550763000_100.7.418.7","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318050d8c2"},{"key":"2024101702550763000_100.7.418.8","doi-asserted-by":"publisher","DOI":"10.1086\/507526"},{"key":"2024101702550763000_100.7.418.9","doi-asserted-by":"publisher","DOI":"10.1310\/98B3-PWG8-PMYW-W5BP"},{"key":"2024101702550763000_100.7.418.10","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn020"},{"key":"2024101702550763000_100.7.418.11","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-8-200704170-00007"},{"key":"2024101702550763000_100.7.418.12","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl386"},{"key":"2024101702550763000_100.7.418.13","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-022-00608-1","article-title":"A clinical review of HIV integrase strand transfer inhibitors (Instis) for the prevention and treatment of HIV-1 infection","volume":"19","author":"Zhao","year":"2022","journal-title":"Retrovirology"},{"key":"2024101702550763000_100.7.418.14","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13593"},{"key":"2024101702550763000_100.7.418.15","doi-asserted-by":"crossref","unstructured":"Maggiolo F , Valenti D , Teocchi R , et al . Real world data on forgiveness to uncomplete adherence to bictegravir\/ emtricitabine\/tenofovir alafenamide. J Int Assoc Provid AIDS Care 2022;21. doi:10.1177\/23259582221140208","DOI":"10.1177\/23259582221140208"},{"key":"2024101702550763000_100.7.418.16","doi-asserted-by":"crossref","unstructured":"Maggiolo F , Valenti D , Teocchi R , et al . Adherence to and forgiveness of 3Tc\/DTG in a real-world cohort. J Int Assoc Provid AIDS Care 2022;21. doi:10.1177\/23259582221101815","DOI":"10.1177\/23259582221101815"},{"key":"2024101702550763000_100.7.418.17","unstructured":"Nau D . Proportion of days covered (PDC) as preferred method of measuring medication adherence, 2011. Available: http:\/\/ep.yimg.com\/ty\/cdn\/epill\/ pdcmpr.pdf [Accessed 17 Feb 2023]."},{"key":"2024101702550763000_100.7.418.18","unstructured":"Pharmacy Quality Alliance (PQA). PQA measure overview, 2019. Available: https:\/\/www.pqaalliance.org\/ adherence-measures [Accessed 17 Feb 2023]."},{"key":"2024101702550763000_100.7.418.19","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S127131"},{"key":"2024101702550763000_100.7.418.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106898"},{"key":"2024101702550763000_100.7.418.21","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2011.0169"},{"key":"2024101702550763000_100.7.418.22","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-014-0873-1"},{"key":"2024101702550763000_100.7.418.23","doi-asserted-by":"publisher","DOI":"10.2165\/11633630-000000000-00000"},{"key":"2024101702550763000_100.7.418.24","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab316","article-title":"Forgiveness of dolutegravir-based triple therapy compared with older antiretroviral regimens: a prospective multicenter cohort of adherence patterns and HIV-RNA replication","volume":"8","author":"Parienti","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2024101702550763000_100.7.418.25","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003062"},{"key":"2024101702550763000_100.7.418.26","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv425"},{"key":"2024101702550763000_100.7.418.27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00496.x"},{"key":"2024101702550763000_100.7.418.28","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2019.02383","article-title":"Persistent HIV-1 viremia on antiretroviral therapy: measurement and mechanisms","volume":"10","author":"Jacobs","year":"2019","journal-title":"Front Microbiol"},{"key":"2024101702550763000_100.7.418.29","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003234"},{"key":"2024101702550763000_100.7.418.30","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002142"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2024-056202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T16:19:08Z","timestamp":1729181948000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2024-056202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,10,17]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/sextrans-2024-056202"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2024-056202","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}